BioSpace News Archive

The report further provides details about each segments and regions covered in the global HCIT Consulting Services market. The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

RightEye, the world’s leading eye-tracking biomarker company, has signed a research collaboration agreement with the Massachusetts Institute of Technology (MIT) to study an oculomotor “signature” for Lyme disease.

Protagonist Therapeutics (Nasdaq: PTGX) today announced topline results from the Phase 2 IDEAL study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Bloom Burton & Co. Healthcare Investor Conference.

Nektar Therapeutics announced a new strategic plan focused on prioritizing key research and development efforts that will be most impactful to the company’s future, including its NKTR-358, NKTR-255 and several core research programs.

Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), today announced two poster presentations at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 23-26, 2022 in Lisbon, Portugal.

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today announced that updated infection data on omidubicel in comparison to umbilical cord blood transplantation (UCB), was shared in an oral presentation at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings.

DBV Technologies announced that the Company will host a conference call and live audio webcast on Monday, May 2, 2022, at 5:00 p.m. ET to report first quarter 2022 financial results and provide a corporate update.

Brand Institute is proud to announce working with Lipocine Inc. in developing the brand name TLANDO®, approved by the Food and Drug Administration (FDA) on March 28, 2022.

Increasing government initiatives to create awareness about the precautionary measures and treatment regarding HIV disease is a key factor driving market revenue growth.